US NIH races to fill nearly half its top roles after wave of departures
On Dec. 15, 2025, the U.S. National Institutes of Health is seeking to fill nearly half of its…
On Dec. 15, 2025, the U.S. National Institutes of Health is seeking to fill nearly half of its…
On Dec. 12, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved two new oral…
On Dec. 11, 2025, USAntibiotics, the country’s only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced…
On Dec. 9, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the…
On Dec. 5, 2025, a federal vaccine advisory committee voted on Friday to end the longstanding recommendation that…
On Dec. 5, 2025, the West Coast Health Alliance (WCHA) announced that it strongly supports that hepatitis B…
On Dec. 4, 2025, Merck Animal Health announced the U.S. Food and Drug Administration (FDA) has granted a…
On Dec. 1, 2025, the U.S. Food and Drug Administration (FDA) announced the deployment of agentic AI capabilities…
On Nov. 28, 2025, The Food and Drug Administration (FDA) announced the withdrawal of the proposed rule entitled…
On Nov. 21, 2025, Pfizer and Astellas Pharma announced that the U.S. Food and Drug Administration (FDA) has…
On Nov. 20, 2025, the US Food and Drug Administration (FDA) has approved the first cancer drug based…
On Nov. 20, 2025, the National Institutes of Health (NIH) has canceled funding for at least 383 clinical…
On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…
On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by…
On Nov. 13, 2025, the U.S. Food and Drug Administration (FDA) approved multiple denosumab biosimilars, enhancing market access…
On Nov. 10, 2025, the Food and Drug Administration (FDA) is reversing a 2003 decision that put a…
On Nov. 6, 2025, Eli Lilly announced an agreement with the U.S. government to expand access to its…
On Nov. 4, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor,…
On Oct. 29, 2025, the U.S. Food and Drug Administration (FDA) announced it is aiming to reduce the…
On Oct. 28, 2025, Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer…
On Oct. 27, 2025, Qureator announced a major milestone, confirming a fundamental shift in drug development under the…
On Oct. 23, 2025, GSK announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf)…
On Oct. 20, 2025, Glaukos announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD…
On Oct. 17, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Rybelsus®, the only oral GLP-1…
On Oct. 16, 2025, the Food and Drug Administration (FDA) announced the first round of experimental drugs that…
On Oct. 13, 2025, the U.S. Food and Drug Administration (FDA) announces it has cleared the Elecsys pTau181…
On Oct. 9, 2025, Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug…
On Oct. 9, 2025, Celltrion announced announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar…
On Oct. 3, 2025, the U.S. Food and Drug Administration (FDA) announced a new pilot prioritization program for…
On Oct. 2, 2025, the U.S. Food and Drug Administration (FDA) approved Evita Solution’s generic version of the…